Loading company…
Stockholm proteomics company developing high-throughput platforms for protein analysis in drug discovery and personalized medicine.
Neoproteomics AB, founded in 2000 in Stockholm, Sweden, develops high-throughput proteomics platforms for analyzing protein structures and functions. Its products support drug discovery, biomarker identification and personalized medicine, serving academic and biotech institutions in North America, Europe and Asia-Pacific. Acacia Asset invested an undisclosed amount in 2014.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in